Table 2.
Univariate and multivariable analysis of molecular, clinical, and composite scores in validation cohorts
| Variable | Meta-cohort microarray validation set |
qPCR validation set | ||
|---|---|---|---|---|
| HR (95% CI) | P* | HR (95% CI) | P* | |
| Univariate | ||||
| MPI (stage I only) | 1.02 (1.01 to 1.03) | <.001 | 1.02 (1.00 to 1.03) | .03 |
| CPI (age, stage, sex) | 3.04 (2.32 to 3.97) | <.001 | 4.24 (2.15 to 8.36) | <.001 |
| Multivariate (all stages) | ||||
| MPI | 1.02 (1.01 to 1.03) | <.001 | 1.02 (1.00 to 1.03) | .009 |
| CPI (age, stage, sex) | 2.72 (2.07 to 3.57) | <.001 | 4.12 (2.12 to 8.00) | <.001 |
| CRM (all stages) | 2.43 (2.05 to 2.88) | <.001 | 2.93 (1.84 to 4.66) | <.001 |
| CRM (high vs low, all stages) | 3.49 (2.50 to 4.88) | <.001 | 4.16 (1.86 to 9.27) | <.001 |
| CRM (stage I) | 2.40 (1.79 to 3.22) | <.001 | 3.15 (1.72 to 5.77) | <.001 |
| CRM (high vs low, stage I) | 3.43 (2.18 to 5.39) | <.001 | 3.99 (1.67 to 9.56) | <.001 |
| CRM (stage IA) | 2.86 (1.69 to 4.82) | <.001 | 4.76 (1.89 to 12.01) | <.001 |
| CRM (high vs low, stage IA) | 3.16 (1.54 to 6.49) | <.001 | 3.84 (1.28 to 11.47) | .009 |
* Two-sided likelihood-ratio test. CI = confidence interval; CPI = clinical prognostic index; CRM = composite risk model; HR = hazard ratio; MPI = molecular prognostic index; qPCR = quantitative polymerase chain reaction.